Skip to content

Myriad Genetics MYGN Cumulative Cost Basis

Cumulative Cost Basis at other companies

Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
GeneDx Holdings logo
GeneDx HoldingsWGS
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
Arcus Biosciences logo
Arcus BiosciencesRCUS

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's cumulative cost basis?
Myriad Genetics (MYGN) reported cumulative cost basis of $202M in Q1 2026.
How has Myriad Genetics's cumulative cost basis changed year-over-year?
Myriad Genetics's cumulative cost basis increased by 2.3% year-over-year, from $197.5M to $202M.
What is the long-term trend for Myriad Genetics's cumulative cost basis?
Over 5 years (2020 to 2025), Myriad Genetics's cumulative cost basis has grown at a 5.6% compound annual growth rate (CAGR), from $153.6M to $201.9M.